Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice

Cancer Letters

Volumn 326, Issue 1, 2012, Pages 88-95

  Brandon Warner, Elizabeth ^a   Eheim, Ashley L ^a   Foureau, David M ^a   Walling, Tracy L ^a   Schrum, Laura W ^a   McKillop, Iain H ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Alcoholic liver disease; Diethylnitrosamine; Ethanol; Hepatocellular carcinoma; Sex; Silibinin

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; CYTOCHROME P450 2E1; DIETHYLNITROSAMINE; GLUTATHIONE; INTERLEUKIN 6; MALONALDEHYDE; SILIBININ;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; SEX DIFFERENCE; SILYBUM MARIANUM;

ALCOHOL DRINKING; ANIMALS; ANTIOXIDANTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; ETHANOL; FEMALE; LIVER NEOPLASMS; MALE; MICE; MILK THISTLE; SEX CHARACTERISTICS; SILYMARIN; TUMOR BURDEN;

MUS; SILYBUM MARIANUM;

EID: 84866179871     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.028     Document Type: Article

References (44)

1. El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011, 365:1118-1127.
2. Yang J.D., Roberts L.R. Hepatocellular carcinoma: a global view. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:448-458.
3. McKillop I.H., Moran D.M., Jin X., Koniaris L.G. Molecular pathogenesis of hepatocellular carcinoma. J. Surg. Res. 2006, 136:125-135.
4. Cornella H., Alsinet C., Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. Alcohol., Clin. Exp. Res. 2011, 35:821-825.
5. McKillop I.H., Schrum L.W. Role of alcohol in liver carcinogenesis. Semin Liver Dis. 2009, 29:222-232.
6. Cederbaum A.I. Role of CYP2E1 in ethanol-induced oxidant stress, fatty liver and hepatotoxicity. Dig. Dis. 2010, 28:802-811.
7. Behrend L., Henderson G., Zwacka R.M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans. 2003, 31:1441-1444.
8. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011, 141:1572-1585.
9. Wu D., Cederbaum A.I. Oxidative stress and alcoholic liver disease. Semin Liver Dis. 2009, 29:141-154.
10. Mandrekar P., Szabo G. Signalling pathways in alcohol-induced liver inflammation. J. Hepatol. 2009, 50:1258-1266.
11. Reuter S., Gupta S.C., Chaturvedi M.M., Aggarwal B.B. Oxidative stress, inflammation, and cancer: how are they linked?. Free Radic. Biol. Med. 2010, 49:1603-1616.
12. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol. Asp. Med. 2008, 29:9-16.
13. Müller C. Liver, alcohol and gender. WMW - Wien. Med. Wschr. 2006, 156:523-526.
14. Harada S., Tachiyashiki K., Imaizumi K. Effect of sex hormones on rat liver cytosolic alcohol dehydrogenase activity. J. Nutr. Sci. Vitaminol. (Tokyo) 1998, 44:625-639.
15. Ellefson W.M., Lakner A.M., Hamilton A., McKillop I.H., Bonkovsky H.L., Steuerwald N.M., Huet Y.M., Schrum L.W. Neonatal androgenization exacerbates alcohol-induced liver injury in adult rats, an effect abrogated by estrogen. PLoS One 2011, 6:e29463.
16. Brandon-Warner E., Walling T.L., Schrum L.W., McKillop I.H. Chronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis. Alcohol. Clin. Exp. Res. 2012, 36:641-653.
17. Cederbaum A.I. Hepatoprotective effects of S-adenosyl-l-methionine against alcohol- and cytochrome P450 2E1-induced liver injury. World J. Gastroenterol. 2010, 16:1366-1376.
18. Abenavoli L., Capasso R., Milic N., Capasso F. Milk thistle in liver diseases: past, present, future. Phytother. Res. 2010, 24:1423-1432.
19. Jacobs B., Dennehy C., Ramirez G., Sapp J., Lawrence V. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am. J. Med. 2002, 113:506-515.
20. Saller R., Brignoli R., Melzer J., Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed. 2008, 15:9-20.
21. Brandon-Warner E., Sugg J.A., Schrum L.W., McKillop I.H. Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma. Cancer Lett. 2010, 291:120-129.
22. Fausto N., Campbell J.S. Mouse models of hepatocellular carcinoma. Semin Liver Dis. 2010, 30:87-98.
23. McKillop I., Shrum L.W. Alcohol and liver cancer. Alcohol 2005, 35:195-203.
24. Severi T., van Malenstein H., Verslype C., van Pelt J.F. Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets. Acta Pharmacol. Sin. 2010, 31:1409-1420.
25. Jayaraj R., Deb U., Bhaskar A.S., Prasad G.B., Rao P.V. Hepatoprotective efficacy of certain flavonoids against microcystin induced toxicity in mice. Environment. Toxicol. 2007, 22:472-479.
26. Seeff L.B., Lindsay K.L., Bacon B.R., Kresina T.F., Hoofnagle J.H. Complementary and alternative medicine in chronic liver disease. Hepatology 2001, 34:595-603.
27. Strader D.B., Bacon B.R., Lindsay K.L., La Brecque D.R., Morgan T., Wright E.C., Allen J., Khokar M.F., Hoofnagle J.H., Seeff L.B. Use of complementary and alternative medicine in patients with liver disease. Am. J. Gastroenterol. 2002, 97:2391-2397.
28. Thompson K.J., Lakner A.M., Cross B.W., Tsukada S., Rippe R.A., McKillop I.H., Schrum L.W. S-adenosyl-l-methionine inhibits collagen secretion in hepatic stellate cells via increased ubiquitination. Liver Int. 2011, 31:891-901.
29. Kono H., Wheeler M., Rusyn I., Lin M., Seabra V., Rivera C., Bradford B., Forman D., Thurman R. Gender differences in early alcohol-induced liver injury: role of CD14, NF-kB, and TNFa. Am. J. Physiol. - Gastrointestinal Liver Physiol. 2000, 278:G652-G661.
30. Rogers C.Q., Ajmo J.M., You M. Adiponectin and alcoholic fatty liver disease. IUBMB Life 2008, 60:790-797.
31. Naugler W., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
32. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J. Hepatol. 2008, 48:380-381.
33. Nakagawa H., Maeda S., Yoshida H., Tateishi R., Masuzaki R., Ohki T., Hayakawa Y., Kinoshita H., Yamakado M., Kato N., Shiina S., Omata M. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int. J. Cancer 2009, 125:2264-2269.
34. Arteel G.E. Oxidants and antioxidants in alcohol-induced liver disease. Gastroenterology 2003, 124:778-790.
35. Gazak R., Walterova D., Kren V. Silybin and silymarin - new and emerging applications in medicine. Curr. Med. Chem. 2007, 14:315-338.
36. Saller R., Melzer J., Reichling J., Brignoli R., Meier R. An updated systematic review of the pharmacology of silymarin. Forsch Komplementmed. 2007, 14:70-80.
37. Wu J.W., Lin L.C., Hung S.C., Lin C.H., Chi C.W., Tsai T.H. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metabol. Disposition: Biol. Fate Chem. 2008, 36:589-596.
38. Zhao J., Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 1999, 20:2101-2108.
39. Jovic A., Howell B., Cote M., Wade S.M., Mehta K., Miyawaki A., Neubig R.R., Linderman J.J., Takayama S. Phase-locked signals elucidate circuit architecture of an oscillatory pathway. PLoS Comput. Biol. 2010, 6:e1001040.
40. Ferenci P., Dragosics B., Dittrich H., Frank H., Benda L., Lochs H., Meryn S., Base W., Schneider B. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol. 1989, 9:105-113.
41. Wabuyele M.B., Yan F., Vo-Dinh T. Plasmonics nanoprobes: detection of single-nucleotide polymorphisms in the breast cancer BRCA1 gene. Anal. Bioanal. Chem. 2010, 398:729-736.
42. Lauren D.R., Martin R.J., Smith W.A., Jensen D.J., Deo B., Douglas J.A. Factors influencing silymarin content and composition in variegated thistle (Silybum marianum). NZ. J. Crop Horticulture Sci. 2006, 34:239-245.
43. Lee J., Hsu B.H., Wu D., Barrett J.S. Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. A 2006, 26:57-68.
44. Tournas V.H., Sapp C., Trucksess M.W. Occurrence of aflatoxins in milk thistle herbal supplements. Food Addit. Contam. Part A, Chem. Anal. Control Expo. Risk Assess. 2012, 29:994-999.